When Camelids bring their antibodies to treatment of animal and zoonotic diseases: the ZooBodies® concept
First innovative collaboration in this field between BioSourcing and VIB
Brussels, October 13, 2017 – Today, BioSourcing, a leading biotech company, announces that it has launched a collaboration with VIB, the Belgium well-known life science research institute, to develop camelid single domain antibodies (VHH), against specific targets associated with inflammatory diseases in animals.
Camelid single domain antibodies (VHH) have repeatedly demonstrated their efficacy in human health and have contributed to date to more than 300 peer-reviewed publications in high ranking journals and the creation of several biotech companies. Their ability to block an identified target effectively and their stability, combined with their affordable production cost in large quantities, will drive them to become the next successful innovative class of Animal Health Biopharmaceuticals.
BioSourcing strongly believes in the considerable potential of Biopharmaceuticals in animal health and has a robust research program of high potential therapeutic proteins at various stages of development. VIB combines its great interest in developing new technologies with a strong focus on translating the results of its basic research activities in benefit for society.
The global animal health market is estimated at about USD 30 billion, growing annually at 4-5%. It is poised for all major innovations driven by biopharmaceuticals, from offering better care for our aging pets, to helping address the challenges of sustainable development in livestock (for example antibiotic resistance, zoonotic diseases).
Dr Gholamreza Hassanzadeh, Manager of the VIB Nanobody® Core, said:
We are happy to collaborate with Bio-Sourcing to develop single domain antibodies in the field of Animal Health. We are convinced of the success of our collaboration thanks to the great potential of camelid single domain antibodies, the experience we have gained to develop human therapeutics, and the development skills of the BioSourcing team.
Dr. Bertrand Mérot, BioSourcing Founder and CEO said:
We are particularly happy to initiate with VIB the first project of our ZooBodies® platform, from which several programs are ongoing. We are convinced this type of molecule can bring advantageous and innovative solutions to the global One’s Health challenge.
About VIB :
About BioSourcing :